SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intels weaker-than-expected outlook after its quarterly reportciting softness in the PC market and manufacturing constraintshas driven a sharp selloff despite stronger data-center demand. Traders are split between viewing the drop as an overreaction and expecting further declines as near-term growth and execution concerns weigh on sentiment.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is drawing attention after reports of a major Binance security breach coincided with a sharp crypto selloff, prompting concerns about exchange security and confidence across the sector. Traders are split between warning of further downside and treating the pullback as a buying opportunity, with some arguing the incident affected an exchange rather than Bitcoin itself.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisks strong quarterly results and raised outlook were followed by a sharp selloff, prompting widespread frustration that the stock fell despite the beat. Traders debate whether broader tech weakness and profit-taking explain the move, while some cite concerns about memory pricing and Kioxias outlook; others argue demand and fundamentals remain strong.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoin weakness tied to reports of a major Binance security incident is weighing on MSTR alongside mixed Q3 results: revenue missed, while reported profit was largely driven by gains on Bitcoin holdings, and the company disclosed a CFO transition. Traders are split between viewing the selloff as a crypto-driven buying opportunity and citing dilution, dividend obligations, and leadership uncertainty as reasons for caution.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons quarterly results and outlook have weighed on the stock, as investors focus on heavy AI infrastructure spending and negative free cash flow despite accelerating AWS growth. Traders are divided between concern that spending may outrun returns and views that the selloff is an overreaction to investment in a fast-growing cloud business.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples unusual resilience while other mega-cap and AI stocks sell off is widely attributed by traders to a rotation into the stock as a safe haven and an anti-AI-capex hedge. The strength is drawing skepticism over its high valuation and whether it can hold up through earnings, while bulls view its cash generation and lower AI spending as defensive advantages.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Weak technology earnings and doubts about returns on heavy AI spendingparticularly after Amazon and Intel resultsare fueling concern about a broader tech-led pullback. Traders are split between calling it an AI-trade unwind and treating the decline as a buyable dip, with some noting SPY has held up better than tech-heavy QQQ.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddits selloff follows weaker-than-expected fourth-quarter revenue guidance, a miss on user growth, and managements warning that Google search referrals are declining; plans to test logged-in-only access have added concern that traffic could fall further. Traders are debating whether the reaction is excessive given strong revenue growth, while many focus on the risks to users and future growth.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Weak Amazon and Intel results have intensified selling across technology and chip stocks, with traders focused on whether heavy AI infrastructure spending will generate adequate returns. The community is debating whether the pullback signals an AI-trade bubble bursting or a buying opportunity, while some also cite rising oil and geopolitical uncertainty as added pressure.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivians quarterly results beat expectations as R2 deliveries ramped, and the company raised its full-year delivery outlook, prompting optimism about improving execution and growth. Traders remain divided over whether the stronger outlook can offset ongoing losses and cash burn, while some also caution that the post-earnings move may fade; speculation about a Walmart van deal remains unconfirmed.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's Why You Should Add ANRO Stock to Your Portfolio Now

Alto advances its depression drug pipeline, with key 2027 study results ahead for ALTO-207, ALTO-300 and ALTO-100.

Are Medical Stocks Lagging  Cardinal Health (CAH) This Year?

Here is how Cardinal Health (CAH) and Alto Neuroscience, Inc. (ANRO) have performed compared to their sector so far this year.

Alto Neuroscience Announces Participation in Upcoming Investor Conferences

Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Companys management team will participate in the following upcoming investor...

Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer

Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company developing novel precision medicines for neuropsychiatric disorders, today announced the promotion of Nick Smith to president and chief financial officer, effective August 26, 2026. Mr. Smith will continue to lead...

Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended June 30, 2026, and highlighted recent progress across its pipeline...

Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock

Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options, announced today the pricing of an underwritten registered direct offering of...

Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia

Alto Neuroscience, Inc. (Alto) (NYSE: ANRO) today highlighted the publication in Nature Medicine of PRIME-PRAXOL, an independent, randomized, double-blind, placebo-controlled trial of the dopamine agonist pramipexole in patients with mood disorders and clinically significant anhedonia. The study...

Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors

Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Andrew Miller, Ph.D. to its Board of Directors, effective May 27, 2026. We are thrilled...

Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award

Alto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today congratulates founder and CEO Amit Etkin, M.D., Ph.D. on receiving the Transformational Research Award from the VP&S Alumni...

Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights

Alto Neuroscience, Inc. (Alto) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported...

Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of psychiatric drugs. Its pipeline is composed of five clinical-stage assets which initially target depressive disorder and schizophrenia population. The company was founded by Amit Etkin, Dan Segal, and Wei Wu on March 25, 2019 and is headquartered in Mountain View, CA.

Alto Neuroscience Inc.

ANRO Stock Drops 7% After Disappointing Schizophrenia Study Results – But Analyst Sees Dip As Attractive Entry Point

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>H.C. Wainwright said the failure of ALTO-101 in its Phase 2 study does not change its overall view on Alto Neuroscience.</li><li>Baird cut Alto’s price target to $38 from $41 but said the company’s depression pipeline remains the key driver of its valuation.</li><li>Jones Research’s latest price target implies a potential 100% upside to the stock’s current price.</li></ul>Shares of Alto Neuroscience (ANRO) slid about 7% on Thursday after disappointing results from a schizophrenia treatment study prompted multiple brokerages to become more cautious on the stock.On Wednesday, Alto Neuroscience <a href="https://stocktwits.com/news-articles/markets/equity/alto-neuroscience-schizophrenia-study-fails/cZ7HygQRIFi">said</a> its experimental schizophrenia drug ALTO-101 failed to meet key goals in a Phase 2 Proof-of-Concept study. ALTO-101 did not show meaningful improvements in brain activity or cognitive measures compared to placebo.As a result, the biotech firm will not continue developing the drug for this use and will shift focus to other programs, including ALTO-207 for treatment-resistant depression. The company is also exploring partnership opportunities for a modified version of ALTO-101 that showed better safety and drug behavior.<h2 class="st-heading-2">Analyst Sees Pullback As Attractive Entry Point</h2>Jones Research cut Alto Neuroscience’s price target to $44 from $49, but kept a ‘Buy’ rating, according to The Fly. This implies a potential 100% upside to the stock’s current price of around $22.Analyst Justin Walsh said that while the stock’s weakness is justified, the market is underestimating Alto’s broader pipeline and sees the pullback as an attractive entry point.H.C. Wainwright said the failure of ALTO-101 in its Phase 2 study does not change its overall view on Alto Neuroscience, as the program was not a key part of its valuation, according to The Fly. The brokerage also highlighted the company’s strong cash position of $275 million, which supports its pipeline. H.C. Wainwright maintained its ‘Buy’ rating and $50 price target.Baird cut the company’s price target to $38 from $41 and maintained an ‘Outperform’ rating. Analyst Brian Skorney called the ALTO-101 Phase 2 failure disappointing, though expectations were already modest given the challenges in schizophrenia treatment. The firm said Alto’s depression pipeline remains the key driver of its valuation.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Despite the intraday decline, retail sentiment for <a href="https://stocktwits.com/symbol/ANRO">ANRO</a> on Stocktwits turned ‘bullish’ from ‘neutral’ a day earlier, amid ‘extremely high’ message volumes.One user had expected a bigger drop.<stembedurl>https://stocktwits.com/Stef_DL/message/649289943</stembedurl>Year-to-date, the stock has gained more than 20%.Read also: <a href="https://stocktwits.com/news-articles/equity/markets/snbr-stock-on-track-to-decline-for-12th-straight-session/cZ7x67bRI8o">SNBR Stock On Track To Decline For 12th Straight Session – Retail Sees Buying Opportunity If Stock Dips Below $1</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Alto Neuroscience logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Alto Neuroscience’s experimental schizophrenia drug ALTO-101 failed to meet key goals in a Phase 2 study, leading to price target cuts from multiple brokerages.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$23.47
Prev Close	$23.33
Open	$23.46
Dividend Yield	0.00%
50-Day Moving Average	$28.51
Beta	1.68
Avg. Volume	594,999.29
PE Ratio	-9.49

52-Week High	$37.48
52-Week Low	$10.20
Market Capitalization	$921.01M
EPS (Annual)	-$2.19
Price to Book	3.76
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

ANRO Fundamentals